LONDON: Shield Therapeutics plc (LSE: STX), a commercial stage pharmaceutical company specialising in iron deficiency, announces that Anders Lundstrom has been appointed as Chief Executive Officer (CEO) with effect from 01 February 2025. Anders joined the Board of Shield in May 2021 and was appointed as interim Chief Executive Officer on 24 July 2024. He…
All posts tagged Shield Therapeutics
Shield Therapeutics commences trading at OTCQX Best Market
LONDON: Shield Therapeutics plc (LON: STX) announced that trading in the Company’s Ordinary Shares of nominal value of £0.015 each began on the OTCQX Best Market (OTCQX) in the United States, under the ticker symbol “SHIEF”. By trading on the premium OTCQX, Shield’s shares will be available to US investors during US working hours and…